CTIC News 2.59 05/19/2014 04:39:59 Cell Therapeutics (CTIC)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cell Therapeutics (CTIC) 2.59 $CTIC

Biotech Stock Mailbag: Sarepta, F-R Rule Stock Predictions, Merrimack
at The Street - Fri May 09, 5:00AM CDT
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Technical Coverage on Biotech Stocks -- Research on Celgene, Cell Therapeutics, Geron, and BioMarin Pharma
PR Newswire - Tue May 06, 8:15AM CDT
The trading session on Monday, May 05, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,530.55, up 0.11% and the NASDAQ Composite closed at 4,138.06, up 0.34%. The S&P 500 finished the day 0.19% higher at 1,884.66. The gains were broad based as eight out of ten sectors finished on a positive note. The S&P 500 Health Care Sector Index ended the day 0.56% higher at 672.57, and the index has gained 5.56% in the previous three months. Investor-Edge has initiated coverage on the following equities: Celgene Corporation (NASDAQ: CELG), Cell Therapeutics Inc. (NASDAQ: CTIC), Geron Corporation (NASDAQ: GERN) and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). Free technical research on CELG, CTIC, GERN and BMRN can be downloaded upon signing up at:

Cell Therapeutics Reports First Quarter 2014 Financial Results
PR Newswire - Tue Apr 29, 3:01PM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the first quarter ended March 31, 2014.

Furiex Pharmaceuticals (FURX) Surges: Stock Moves 28.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 8:21AM CDT
Furiex Pharmaceuticals, Inc. (FURX) was a big mover last session, as the company saw its shares rise by roughly 29% on the day.

PIXUVRI(R) Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire Europe - Tue Apr 29, 3:03AM CDT
- First and Only Approved Monotherapy in the EU for this Patient Population -

PIXUVRI® Launched In UK For Adult Patients With Multiply Relapsed Or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
PR Newswire - Tue Apr 29, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced the launch of PIXUVRI® (pixantrone), the first new treatment for adult patients in the United Kingdom (UK) with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (aggressive B-cell NHL), at the 54th annual scientific meeting of the British Society for Haematology.

Cell Therapeutics to Report First Quarter 2014 Financial Results on April 29, 2014
PR Newswire - Tue Apr 22, 12:30AM CDT
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that it will report its first quarter 2014 financial results on Tuesday, April 29, 2014, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. EDT (1:30 p.m. PDT). Access to the event can be obtained as follows:

Shorts Are Piling Into These Stocks. Should You Be Worried?
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 21, 3:46PM CDT
The best thing about the stock market is that you can make money in  either direction . Historically, stock indexes tend to trend upward over the long term. But when you look at individual stocks, you'll find plenty that lose money over the long...

Pacira Pharmaceuticals (PCRX) Soars: Stock Adds 11.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:21AM CDT
Pacira Pharmaceuticals, Inc. (PCRX) was a big mover last session, as the company saw its shares rise by over 11% on the day.

Insider Trading Alert - CTIC, KR And IBKR Traded By Insiders
at The Street - Mon Mar 31, 9:45AM CDT
Stocks with insider trader activity include CTIC, KR and IBKR

Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 28, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday

Insider Trading Research -- Alerts for Ariad Pharmaceuticals, Cell Therapeutics, Staples, Sirius XM, Facebook, and Bank of America
PR Newswire - Tue Mar 25, 7:55AM CDT
Today, Insiderslab.com released the latest insider trading research for Ariad Pharmaceuticals (NASDAQ:ARIA), Cell Therapeutics (NASDAQ:CTIC), Staples (NASDAQ:SPLS), Sirius XM (NASDAQ:SIRI), Facebook (NASDAQ:FB), and Bank of America (NYSE:BAC). US stock investors can access these reports through the links below, including stock performance, insider trading signals, and visual results.

Stock to Watch: Cell Therapeutics Down 5.5% (CTIC)
Comtex SmarTrend(R) - Mon Mar 24, 10:11AM CDT
Cell Therapeutics (NASDAQ:CTIC) is one of today's worst performing low-priced stocks, down 5.5% to $3.60 on 1.3x average daily volume. Cell Therapeutics has traded 6.6 million shares thus far today, vs. average volume of 5.0 million shares per day. The stock has underperformed the Dow (-5.5% to the Dow's -0.2%) and underperformed the S&P 500 (-5.5% to the S&P's -0.6%) during today's trading.

What's Next for Geron and Imetelstat?
Sean Williams, The Motley Fool - Motley Fool - Wed Mar 19, 11:05AM CDT
It's been a volatile year for clinical-stage cancer-focused biopharmaceutical company Geron , whose shares moved lower by 60% last week following the announcement of a full clinical hold of its only clinical compound, imetelstat, and rocketed...

Initiation of Clinical Trials, Completed Acquisitions, Financial Results, and Earnings Release Schedules - Analyst Notes on Cell Therapeutics, Intrexon, Chimerix, Receptos, and Revance Therapeutics
PR Newswire - Tue Mar 18, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Cell Therapeutics, Inc. (NASDAQ: CTIC), Intrexon Corporation (NYSE: XON), Chimerix, Inc. (NASDAQ: CMRX), Receptos, Inc. (NASDAQ: RCPT), andRevance Therapeutics, Inc. (NASDAQ: RVNC). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Investor-Edge.com Most Active Equities Watch List: Cell Therapeutics, Yandex, Himax Technologies, and CytRx
PR Newswire - Fri Mar 14, 7:54AM CDT
The trading session on Thursday, March 13, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,108.89, down 1.41% and the NASDAQ Composite closed at 4,260.42, down 1.46%. The S&P 500 finished the session 1.17% lower at 1,846.34. The losses were broad based as nine of ten sectors ended the session in negative. Investor-Edge.com looks at some of the equities which were most active during the session. These include Cell Therapeutics Inc. (NASDAQ:CTIC), Yandex N.V. (NASDAQ:YNDX), Himax Technologies Inc. (NASDAQ:HIMX), and CytRx Corp. (NASDAQ:CYTR). Free research on these four companies can be accessed at:

Geron: FDA Suspends Key Myelofibrosis Drug Due to Liver Safety Concerns
at The Street - Wed Mar 12, 8:57AM CDT
The FDA's clinical hold placed on Geron's imetelstat means all clinical trials are suspended.

Insider Trading Alert - CTIC, TCBI And FCS Traded By Insiders
at The Street - Mon Mar 10, 12:16PM CDT
Stocks with insider trader activity include CTIC, TCBI and FCS

Cell Therapeutics to Present at the 26th Annual ROTH Conference
PR Newswire - Wed Mar 05, 12:30AM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) announced today that management will present at the ROTH Capital Partners 26th Annual Conference on Tuesday, March 11 at 11:30 a.m. PST/2:30 p.m. EST/7:30 p.m. CET in Dana Point, CA.

Cell Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Tue Mar 04, 3:00PM CST
Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today reported financial results for the fourth quarter and full year ended December 31, 2013.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
KINGRVER Boosts RV Comfort with New Water Heater Lineup

Updated Category News Views 328

An Upgrade for the Open Road In the land of RV living, comfort is king—or in this case, KINGRVER. Dropping affordable upgrades for water heaters into the world of RVs, KINGRVER's CT6 lineup is like a warm hug on a chilly campsite morning. Whether you've pulled up to a wooded retreat or parked under the vast desert sky, having dependable hot water shouldn't be a gamble....

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 258

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 459

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Innovent's Big Leap: Targeting European Lung Cancer Market

Updated Category News Views 131

Innovent's Regulatory Milestone in Europe They say every underdog has its day, and for Innovent Biologics, that time just might be now. Receiving a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) is no small potatoes. Especially when we're talking lung cancer—a notorious heavyweight in the cancer world. The Finer Details of Zybrivo’s...

Continue Reading
CVS Study: GLP-1 Drugs Effective But Costly

Updated Category News Views 157

Can GLP-1s Deliver Value at Their Current Price? Alright, folks, here's a real-world gut check from CVS Health. They crunched some numbers using Aetna's anonymized claims data, and the results are eye-opening. These GLP-1s are showing promising health outcomes—lower hospital visits, better clinical results, yada yada. But when it comes to savings, they ain't quite...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 121

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 332

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 509

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 250

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading

Top 5 Most Recently Viewed Articles

Atlanticus Holdings Celebrates Substantial Year-End Growth

Updated Category News Views 176

Impressive Financial Results for Atlanticus Holdings Atlanticus Holdings Corporation (NASDAQ: ATLC), known for empowering financial inclusivity through innovative technology, has reported remarkable achievements in its financial results for the fourth quarter and the full year ended December 31, 2024. The company served an impressive total of 3.7 million accounts,...

Continue Reading
Jonas Warrer Expands Stake in Gentoo Media: Key Insights

Updated Category News Views 262

Jonas Warrer's Strategic Move in Gentoo Media Holdings Recent transactions in the stock market have captivated the attention of many investors, particularly when they involve significant figures in the industry. One such notable event occurred when Jonas Warrer, CEO and primary insider of Gentoo Media, made headlines by acquiring a substantial number of shares in his own...

Continue Reading
Venture Global Inc. Faces Class Action Over Investor Losses

Updated Category News Views 233

Venture Global Inc. Investors Advised on Class Action For investors in Venture Global Inc. seeking justice, significant legal developments have unfolded. The company, known for its ambitious initiatives in the liquefied natural gas sector, is currently facing serious allegations in a class action lawsuit. For those who lost money in their investments, it's crucial to...

Continue Reading
Global Roaming Tariff Market Expected to Hit USD 140.3 Billion

Updated Category News Views 329

Overview of the Roaming Tariff Market Growth The Roaming Tariff Market has entered an exciting phase, anticipated to soar to USD 140.3 billion by 2032, after reaching USD 77.5 billion in 2023. Such growth, at a compound annual growth rate (CAGR) of 6.83% from 2024 to 2032, is invigorated by the widespread expansion of 5G technology and increasing global travel demand. Key...

Continue Reading
Investing Insights: Analyzing Charles Schwab's Market Position

Updated Category News Views 263

Understanding the Recent Shift in Charles Schwab's Market Position Charles Schwab's short percent of float has recently experienced a significant increase, rising by 67.5% as indicated by the latest reports. Currently, there are 22.74 million shares sold short, which accounts for 1.34% of the total regular shares available for trading. With this short interest, traders...

Continue Reading